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Abstract

Key Points

IMPORTANCE Limited data are available about the outcomes of mechanical thrombectomy (MT) for
real-world patients with stroke presenting with a large core infarct.

Question What is the 90-day outcome
for patients with stroke presenting with
an Alberta Stroke Program Early

OBJECTIVE To investigate the safety and effectiveness of MT for patients with large vessel occlusion
and an Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of 2 to 5.

Computed Tomography Score
(ASPECTS) of 2 to 5 who underwent
mechanical thrombectomy?

DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used data from the Stroke

Findings In this multicenter cohort

Thrombectomy and Aneurysm Registry (STAR), which combines the prospectively maintained

study of 2345 patients presenting with

databases of 28 thrombectomy-capable stroke centers in the US, Europe, and Asia. The study

an intracranial internal carotid artery or

included 2345 patients presenting with an occlusion in the internal carotid artery or M1 segment of

M1 occlusion who underwent

the middle cerebral artery from January 1, 2016, to December 31, 2020. Patients were followed up for

mechanical thrombectomy, 213 [9.1%]

90 days after intervention. The ASPECTS is a 10-point scoring system based on the extent of early

had an ASPECTS of 2 to 5, and 22% of

ischemic changes on the baseline noncontrasted computed tomography scan, with a score of 10

these patients achieved favorable

indicating normal and a score of 0 indicating ischemic changes in all of the regions included in

90-day outcomes (modified Rankin

the score.

scale score of 0-2). Patients who
achieved successful recanalization were
nearly 5 times more likely to achieve

EXPOSURE All patients underwent MT in one of the included centers.

favorable outcomes compared with

MAIN OUTCOMES AND MEASURES A multivariable regression model was used to assess factors

patients who had unsuccessful

associated with a favorable 90-day outcome (modified Rankin Scale score of 0-2), including

recanalization.

interaction terms between an ASPECTS of 2 to 5 and receiving MT in the extended window (6-24
hours from symptom onset).

Meaning This study suggests that
patients with a low ASPECTS on
presentation may achieve 90-day

RESULTS A total of 2345 patients who underwent MT were included (1175 women [50.1%]; median
age, 72 years [IQR, 60-80 years]; 2132 patients [90.9%] had an ASPECTS of ⱖ6, and 213 patients
[9.1%] had an ASPECTS of 2-5). At 90 days, 47 of the 213 patients (22.1%) with an ASPECTS of 2 to 5

functional independence after
mechanical thrombectomy if they
achieve successful recanalization.

had a modified Rankin Scale score of 0 to 2 (25.6% [45 of 176] of patients who underwent successful
recanalization [modified Thrombolysis in Cerebral Ischemia score ⱖ2B] vs 5.4% [2 of 37] of patients
who underwent unsuccessful recanalization; P = .007). Having a low ASPECTS (odds ratio, 0.60;
95% CI, 0.38-0.85; P = .002) and presenting in the extended window (odds ratio, 0.69; 95% CI,
0.55-0.88; P = .001) were associated with worse 90-day outcome after controlling for potential
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Abstract (continued)

CONCLUSIONS AND RELEVANCE In this cohort study, more than 1 in 5 patients presenting with an
ASPECTS of 2 to 5 achieved 90-day functional independence after MT. A favorable outcome was
nearly 5 times more likely for patients with low ASPECTS who had successful recanalization. The
association of a low ASPECTS with 90-day outcomes did not differ for patients presenting in the early
vs extended MT window.
JAMA Network Open. 2021;4(12):e2137708. doi:10.1001/jamanetworkopen.2021.37708

Introduction
Clinical trials have shown that mechanical thrombectomy (MT) is associated with improved
functional outcomes for patients with acute ischemic stroke presenting with proximal anterior
circulation, large vessel occlusion, and salvageable brain tissue.1-5 As a result, MT has become the
standard of care for these patients since 2015.1,6 The Alberta Stroke Program Early Computed
Tomography Score (ASPECTS) is a 10-point scoring system based on the extent of early ischemic
changes detected on the baseline noncontrasted computed tomography scan, with a score of 10
indicating normal and 0 indicating ischemic changes in all of the regions included in the score.7
Patients with an ASPECTS lower than 6 were excluded from most clinical trials8; therefore, data
about their outcomes remain scarce, and whether these patients could still achieve benefits from MT
remains unknown.4 The rationale behind excluding this group of patients stems from the knowledge
that patients with a large core infarct at presentation are unlikely to benefit from reperfusion to the
same degree as those with either a small core infarct or no core infarct.9 However, the infarct size
threshold for futility remains unknown.
Results from the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular
Stroke) collaboration suggested potential benefits associated with MT for patients with a low
baseline ASPECTS, but the results were limited by the small number of patients with low ASPECTS.4,8
Other observational studies have suggested potential benefits associated with MT in this group.10-14
Similarly, these studies were limited by the small sample size and the limited number of patients
treated in the extended MT window (6-24 hours from symptom onset to groin puncture). In this
study, we sought to investigate the safety and effectiveness of MT in a real-world cohort of patients
with large vessel occlusion and large core infarct in the early thrombectomy window (<6 hours from
symptom onset to groin puncture) and an extended thrombectomy window. We compared the
outcomes of MT for patients with a low vs high ASPECTS using a cutoff of 5 or less for a low ASPECTS
given that this cutoff was used in most of the MT clinical trials, including ESCAPE (Endovascular
Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing
CT to Recanalization Times)15 and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for
Ischemic Stroke).5 Then, we assessed the MT outcomes of patients with a low ASPECTS based on
reperfusion status and treatment in the early vs extended window, hypothesizing that both of these
factors modify the outcome associated with MT.

Methods
Study Design
In this retrospective cohort study, we reviewed the prospectively maintained databases of 28 stroke
centers in the Stroke Thrombectomy and Aneurysm Registry. We included patients with acute stroke
presenting with an occlusion in the internal carotid artery (ICA) or M1 segment of the middle cerebral
artery who received MT within 24 hours of witnessed symptom onset between January 1, 2016, and
December 31, 2020. All patients with an ICA or M1 occlusion underwent MT regardless of their
perfusion status. After MT, patients were admitted to the neurologic intensive care unit in each of the
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included centers. Follow-up head images were obtained 24 hours after MT to assess the presence of
hemorrhagic transformation and cerebral edema. The study was approved by the institutional review
board at each of the included centers (Medical University of South Carolina; Emory University School
of Medicine; Thomas Jefferson University Hospitals; University of Miami Health System; Wake Forest
School of Medicine; University of Tennessee Health Science Center; University of Iowa Hospitals and
Clinics; University Medical Center Göttingen; West Virginia School of Medicine; University of Texas
Health Science Center at San Antonio; University of Basel; Mount Sinai Health System; University of
Arizona; University of Washington; University of Florida; Washington University in St Louis;
Endovascular Neurological Center, Montevideo, Uruguay; Chonnam National University Hospital;
Hospital Juan Fernandez; Hyogo College of Medicine; Yale School of Medicine; University of Texas
Medical Branch; Allegheny Health Network; Centre Hospitalier Régional Universitaire de Nancy;
Centre Hospitalier Régional Universitaire de Nancy; Hospital São José Centro Hospitalar; Bon Secours
Mercy Health St Vincent Medical Center; and Texas Stroke Institute), and the need for informed
consent was waived given its minimal risk design. This study followed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Data Collection and Clinical Outcome
Collected data included baseline demographic characteristics, location of occlusion, baseline core
infarct as determined by the ASPECTS, time from symptom onset to groin puncture, MT technique,
procedure time, thrombectomy passes, devices used, rescue therapy used, complications, and final
modified Thrombolysis in Cerebral Ischemia score. Patients with an ASPECTS of 2 to 5 were divided
into early window and extended window groups. Baseline imaging, recanalization rates, and
postprocedural imaging were reviewed by local investigators at each participating site. Successful
recanalization was defined as a modified Thrombolysis in Cerebral Ischemia score of 2B or more. The
90-day modified Rankin Scale (mRS) score was used as the primary outcome measure and was
recorded during a follow-up visit or telephone encounter at a mean (SD) of 90 (14) days after stroke
by a stroke neurologist or registered nurse.16 Favorable outcome was defined as an mRS score of 0
to 2 at 90 days. Symptomatic intracranial hemorrhage was defined as postprocedural hemorrhage
with an associated decrease of 4 points or more in the National Institutes of Health Stroke Scale
(NIHSS) score.

Statistical Analysis
We used descriptive statistics to report patients’ demographic and clinical characteristics, using
median (IQR) values for continuous variables and percentages for categorical variables. The
characteristics of the 2 groups were compared using the Wilcoxon rank sum (Mann-Whitney) test and
the χ2 test as appropriate. We used a multivariable logistic regression model to assess the factors
associated with 90-day outcomes for all patients undergoing MT who presented with ICA or M1
occlusion, and interaction terms between an ASPECTS of 2 to 5 and receipt of MT in the extended
window were used. Variables included in the regression model include age, location of occlusion,
admission NIHSS score, intravenous thrombolysis, successful recanalization, an ASPECTS of 2 to 5,
and treatment in the extended window. Finally, to assess whether the association between an
ASPECTS of 2 to 5 and a favorable outcome is modified by the center in which the thrombectomy was
performed, we used the Cochran-Mantel-Haenszel test. All P values were from 2-sided tests, and
results were deemed statistically significant at P < .05.

Results
A total of 6660 patients who underwent MT were included in the Stroke Thrombectomy and
Aneurysm Registry at the time of the study. Of those, 2351 patients had an occlusion in the ICA or M1
segment of the middle cerebral artery. Patients who presented with an ASPECTS of 0 to 1 (n = 6)
were excluded given that all of them had an mRS score of 5 to 6 on 90-day follow-up, resulting in a
JAMA Network Open. 2021;4(12):e2137708. doi:10.1001/jamanetworkopen.2021.37708 (Reprinted)
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final sample of 2345 patients who underwent MT. Among included patients, the median age was 72
years (IQR, 60-80 years), 1175 (50.1%) were women, 2132 (90.9%) had ASPECTS of 6 or higher, and
213 (9.1%) had an ASPECTS of 2 to 5.

Characteristics and Outcomes for Patients With an ASPECTS of 2 to 5 vs 6 to 10
Patients with an ASPECTS of 2 to 5 were younger (median age, 70 years [IQR, 59-77 years] vs 72 years
[IQR, 60-81 years]; P = .003), had a higher median NIHSS score on presentation (18 [IQR, 14-22] vs
16 [IQR, 12-20]; P < .001), and were more likely to present with an ICA occlusion (102 of 213 [47.9%]
vs 614 of 2132 [28.8%]) compared with patients presenting with an ASPECTS of 6 to 10 (Table 1).
Patients in the low ASPECTS group had a worse 90-day median mRS score than those in the high
ASPECTS group (4 [IQR, 3-6] vs 4 [IQR, 1-5]; P < .001) and higher 90-day mortality (70 of 213 [32.9%]
vs 464 of 2132 [21.8%]; P < .001). At 90 days, 47 of the 213 patients (22.1%) with an ASPECTS of 2 to
5 had an mRS score of 0 to 2, whereas 771 of the 2132 patients (36.2%) with an ASPECTS of 6 to 10
had an mRS score of 0 to 2.

Successful vs Unsuccessful Recanalization in Patients With an ASPECTS of 2 to 5
For the 213 patients with an ASPECTS of 2 to 5, 176 (82.6%) achieved successful recanalization after
MT. No significant difference between the 2 groups was noted in the baseline characteristics,
admission NIHSS score, location of occlusion, intravenous tissue plasminogen activator use, MT
technique, intra-arterial tissue plasminogen activator use, or the number of MT passes (Table 2). A
favorable outcome (90-day mRS score of 0-2) was seen in 45 of 176 patients (25.6%) in the
successful recanalization group compared with only 2 of 37 patients (5.4%) in the unsuccessful
recanalization group (P = .007). There was no significant difference in 90-day mortality between the

Table 1. Characteristics of Patients Who Underwent Mechanical Thrombectomy Presenting With ICA
or M1 Occlusion
Patients, No. (%)
Characteristic

ASPECTS of 6-10
(n = 2132)

ASPECTS of 2-5
(n = 213)

P valuea

Age, median (IQR), y

72 (60-81)

70 (59-77)

.003

Female

1072 (50.3)

103 (48.4)

Male

1060 (49.7)

110 (51.6)

16 (12-20)

18 (14-22)

614 (28.8)

102 (47.9)

Sex

Admission NIHSS score, median (IQR)
Location of occlusion
ICA
M1

.59
<.001
<.001

1518 (71.2)

111 (52.1)

IV-tPA used

1114 (52.3)

98 (46.0)

.08

Time from symptom onset to groin puncture,
median (IQR), min

240 (155-424)

305 (201-566)

<.001

Thrombectomy passes, median (IQR), No.

2 (1-3)

2 (2-3)

<.001

≥2B

1812 (85.0)

176 (82.6)

.36

≥2C

1148 (53.8)

99 (46.5)

.04

Procedure duration, median (IQR), min

38 (23-63)

45 (22-77)

.09

Periprocedural complications

115 (5.4)

16 (7.5)

.20

Symptomatic intracerebral hemorrhage

125 (5.9)

24 (11.3)

.002

Parenchymal hematoma type II

155 (7.3)

33 (15.5)

<.001

Median (IQR)

4 (1-5)

4 (3-6)

<.001

0-2

771 (36.2)

47 (22.1)

<.001

0-3

1051 (49.3)

78 (36.6)

<.001

464 (21.8)

70 (32.9)

<.001

mTICI score

90-d mRS score

Abbreviations: ASPECTS, Alberta Stroke Program Early
Computed Tomography Score; ICA, internal carotid
artery; IV-tPA, intravenous tissue plasminogen
activator; mRS, modified Rankin scale; mTICI, modified
Thrombolysis in Cerebral Ischemia; NIHSS, National
Institutes of Health Stroke Scale.
a

90-d Mortality
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successful recanalization group and the unsuccessful recanalization group (54 of 176 [30.7%] vs 16
of 37 [43.2%]; P = .14).

An ASPECTS of 2 to 5 in the Early and Extended Windows
We divided patients with a low ASPECTS undergoing MT into early (ⱕ6 hours) and extended (6-24
hours) window groups (Table 3). There was no significant difference between patients in the early
window group and patients in the extended window group in 90-day favorable outcome (30 of 123
[24.4%] vs 17 of 90 [18.9%]; P = .34) or 90-day mortality (46 of 123 [37.4%] vs 24 of 90
[26.7%]; P = .10).

Multivariable Analysis
Using a binary regression model that included all patients who presented with an ICA or M1 occlusion
and underwent MT, both a low ASPECTS and treatment in the extended window were associated
with lower odds of achieving a favorable 90-day outcome (low ASPECTS: odds ratio [OR], 0.60; 95%

Table 2. Characteristics of Patients Who Underwent Mechanical Thrombectomy Presenting With ICA
or M1 Occlusion and an ASPECTS of 2 to 5 Who Had Successful vs Unsuccessful Recanalization
Patients, No. (%)
Characteristic

Successful recanalization
(n = 176)

Unsuccessful recanalization
(n = 37)

P valuea

Age, median (IQR), y

70 (60-77)

67 (54-76)

.24

Female

82 (46.6)

21 (56.8)

Male

94 (53.4)

16 (43.2)

Black

12 (6.8)

3 (8.1)

White

156 (88.6)

29 (78.4)

Otherb

8 (4.5)

5 (13.5)

Sex
.26

Race

.11

Hypertension

114 (64.8)

28 (75.7)

.20

Type 1 or 2 diabetes

54 (30.7)

13 (35.1)

.60

Atrial fibrillation

57 (32.4)

16 (43.2)

.21

Hyperlipidemia

60 (34.1)

14 (37.8)

.66

Admission NIHSS score, median (IQR)

18 (14-22)

18 (14-21)

.50

ICA

82 (46.6)

20 (54.1)

M1

94 (53.4)

17 (45.9)

IV-tPA used

81 (46.0)

17 (45.9)

.99

Time from symptom onset to groin
puncture, median (IQR), min

299 (200-519)

345 (224-629)

.36

ADAPT

128 (72.7)

25 (67.6)

Stent retriever

15 (8.5)

5 (13.5)

Solumbra

5 (2.8)

2 (5.4)

Combination of techniques

Location of occlusion
.41

Technique

.65

28 (15.9)

5 (13.5)

IA-tPA used

9 (5.1)

2 (5.4)

.94

Thrombectomy passes, median (IQR), No.

2 (2-3)

2 (2-3)

.23

Procedure duration, median (IQR), min

39 (19-77)

65 (40-78)

.01

Periprocedural complications

10 (5.7)

6 (16.2)

.03

Symptomatic intracerebral hemorrhage

21 (11.9)

3 (8.1)

.50

Median (IQR)

4 (2-6)

5 (4-6)

.001

0-2

45 (25.6)

2 (5.4)

.007

0-3

74 (42.0)

4 (10.8)

<.001

54 (30.7)

16 (43.2)

.14

90-d mRS score

90-d Mortality
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CI, 0.38-0.85; P = .002; extended window: OR, 0.69; 95% CI, 0.55-0.88; P = .001), controlling for
age, location of occlusion, admission NIHSS score, intravenous thrombolysis, and successful
recanalization. However, the interaction between a low ASPECTS and treatment in the extended
window was not significant (OR, 0.85; 95% CI, 0.39-1.78; P = .64) regarding the association with
favorable 90-day outcome. Other factors associated with favorable 90-day mRS score include
younger age (OR, 1.04; 95% CI, 1.03-1.05; P < .001), lower admission NIHSS score (OR, 1.12; 95% CI,
1.10-1.14; P < .001), intravenous thrombolysis (OR, 1.32; 95% CI, 1.07-1.63), and modified
Thrombolysis in Cerebral Ischemia score of 2B or more (OR, 6.64; 95% CI, 4.56-9.66; P < .001). The
eTable in Supplement 1 summarizes results of regression analysis for a 90-day mRS score of 0 to 3.
In addition, a low ASPECTS was associated with a higher risk of 90-day mortality (OR, 2.20;
95% CI, 1.37-3.31; P < .001), controlling for age, location of occlusion, admission NIHSS score,
intravenous thrombolysis, time from symptom onset to groin puncture, and successful
recanalization. However, treatment in the extended window was not independently associated with

Table 3. Characteristics of Patients Who Underwent Mechanical Thrombectomy Presenting With ICA
or M1 Occlusion and an ASPECTS of 2 to 5 Who Presented in the Early vs Extended Window
Time from onset of symptoms to groin puncture, No. (%)
Characteristic

<6 h (n = 123)

6-24 h (n = 90)

P valuea

Age, median (IQR), y

72 (62-78)

66 (55-76)

.01

Female

54 (43.9)

49 (54.4)

Male

69 (56.1)

41 (45.6)

Black

10 (8.1)

5 (5.6)

White

106 (86.2)

79 (87.8)

Otherb

7 (5.7)

6 (6.7)

Sex
.13

Race

.75

Hypertension

79 (64.2)

63 (70.0)

.38

Type 1 or 2 diabetes

35 (28.5)

32 (35.6)

.27

Atrial fibrillation

52 (42.3)

21 (23.3)

.004

Hyperlipidemia

38 (30.9)

36 (40.0)

.17

Admission NIHSS score, median (IQR)

18 (14-22)

18 (13-22)

.64

ICA

63 (51.2)

39 (43.3)

M1

Location of occlusion

.26

60 (48.8)

51 (56.7)

IV-tPA used

90 (73.2)

8 (8.9)

<.001

Time from symptom onset to groin puncture,
median (IQR), min

221 (130-276)

607 (440-864)

NA

ADAPT

87 (70.7)

66 (73.3)

Stent retriever

11 (8.9)

9 (10.0)

Solumbra

4 (3.3)

3 (3.3)

Combination of techniques

Technique

.90

21 (17.1)

12 (13.3)

IA-tPA used

6 (4.9)

5 (5.6)

.83

Thrombectomy passes, median (IQR), No.

2 (2-3)

2 (2-3)

.78

mTICI score ≥2B

103 (83.7)

73 (81.1)

.62

mTICI score ≥2C

59 (48.0)

40 (44.4)

.61

Procedure duration, median (IQR), min

50 (27-92)

34 (18-65)

.007

Periprocedural complications

10 (8.1)

6 (6.7)

.69

Symptomatic intracerebral hemorrhage

18 (14.6)

6 (6.7)

.07

Median (IQR)

5 (3-6)

4 (3-6)

.38

0-2

30 (24.4)

17 (18.9)

.34

0-3

42 (34.1)

36 (40.0)

.38

46 (37.4)

24 (26.7)

.10

90-d mRS score

90-d Mortality
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90-day mortality (OR, 0.95; 95% CI, 0.74-1.23; P = .89). The interaction between a low ASPECTS and
treatment in the extended window was not significant (OR, 0.88; 95% CI, 0.44-1.61; P = .60)
regarding the association with 90-day mortality.

Analysis Based on the Thrombectomy Center
The percentage of patients with an ASPECTS of 2 to 5 who underwent MT compared with all patients
with ICA or M1 occlusion who underwent MT ranged between 4.4% (5 of 113) and 15.2% (48 of 316)
(P = .12). With the Cochran-Mantel-Haenszel test, the association between an ASPECTS of 2 to 5 and
a favorable outcome was not modified by the center in which the MT was performed.

Discussion
In this large, multicenter study assessing the outcomes of patients with large vessel occlusion and a
low ASPECTS treated with MT, patients who achieved successful recanalization were 5 times more
likely to achieve a favorable outcome compared with patients who had an unsuccessful
recanalization, supporting the benefit associated with MT, despite a higher rate of symptomatic
intracranial hemorrhage among patients with a low ASPECTS treated with MT. Furthermore, the
interaction between an ASPECTS of 2 to 5 and treatment in the extended window was not significant,
which reflects that both of these factors are independently associated with outcomes, suggesting
that patients with a larger infarct volume may potentially still achieve benefits associated with MT
even beyond 6 hours from symptom onset.
Although there are 5 ongoing clinical trials—TENSION (NCT03094715), IN EXTREMIS-LASTE
(NCT03811769), TESLA (NCT03805308), SELECT 2 (NCT03876457), and RESCUE-Japan LIMIT
(NCT03702413)—to answer the question about the effectiveness of MT for patients with acute
stroke and a low ASPECTS, our study presents real-world outcome observations from a large,
multicenter registry in the absence of strong evidence for or against MT in this group of patients.
Even though symptomatic intracranial hemorrhage after MT was encountered more often in the low
ASPECTS group, approximately 22% of these patients achieved 90-day functional independence
(mRS score of 0-2) with MT compared with 9% of patients with an ASPECTS of 0 to 7 in the control
group of the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute
Ischemic Stroke in the Netherlands) trial.17
Several studies have evaluated outcomes among patients with a large baseline infarct volume
undergoing MT. Most of these studies are limited by small numbers of patients. Yoo et al17 found no
association between size of ischemic core and treatment effect of endovascular therapy in a post
hoc analysis of the MR CLEAN trial. In addition, a recent meta-analysis of patients undergoing
endovascular therapy within 6 hours of symptom onset demonstrated no reduction in treatment
effect of endovascular therapy with increase in ischemic core volume.18 That meta-analysis also
demonstrated a greater likelihood of favorable functional outcomes across every ischemic core
volume level for endovascular intervention compared with medical therapy alone. In addition, the
clinical benefit associated with a 1-point improvement in the mRS score was maintained up to 150 mL
of estimated ischemic core volume. Our study supports these findings given that approximately 1 in
5 of the patients with an ASPECTS of 2 to 5 achieved a favorable 90-day mRS score of 0 to 2.
Although time from symptom onset and its association with outcome has been studied in great
detail, data regarding the outcomes of patients with a low baseline ASPECTS in the extended MT
window (6-24 hours) are limited. Patients with a low ASPECTS were excluded from both the DAWN
(DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting
Strokes Undergoing Neurointervention With Trevo)3 and DEFUSE 3 trials,5 and even in trials that
included these patients, such as the Optimizing Patient Selection for Endovascular Treatment in
Acute Ischemic Stroke (SELECT) study19—a prospective observational study that assessed the
outcomes of MT for patients with a large core infarction—only 11 patients with an ASPECTS of lower
than 6 were treated with MT in the extended window. Of those patients, only 18% achieved a
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favorable outcome (90-day mRS score of 0-2) compared with 42% of patients with an ASPECTS of
lower than 6 presenting in the early window who underwent MT. Although MT performed in the
extended window was independently associated with a lower likelihood of a favorable outcome in
our study, the interaction between an ASPECTS of 2 to 5 and MT performed in the extended window
was not statistically significant, further demonstrating that both variables are independently
associated with MT outcomes, supporting a more permissive criteria for extended window treatment
selection than those used in DAWN and DEFUSE 3.
In our study, patients with a low ASPECTS who underwent MT in the extended window had
shorter procedure duration compared with those who underwent MT in the early window (34 vs 50
minutes; P = .007). These results can be explained by the fact that patients in the extended window
were younger and that younger patients usually have less tortuous anatomy and fewer access
difficulties.20,21
In our study, younger age was associated with favorable outcomes of MT independently of the
ASPECTS and presenting in the early vs extended window. Similar results were reported in previous
studies that demonstrated that patients younger than 80 years were twice as likely to achieve
functional independence compared with patients older than 80 years of age.22,23 Given the
importance of age in modifying the association of MT with outcomes, it should be considered in
planning and interpretation of clinical trials that study the outcome of MT for patients with a
low ASPECTS.
Collateral status represents a potential factor associated with MT outcomes for patients with a
low ASPECTS. A study by Broocks et al24 included 100 patients with an ASPECTS of 5 or lower
undergoing MT and found that those with a good collateral score were more likely to experience
benefits associated with successful recanalization. In addition, the authors found that good collateral
scores were associated with attenuated edema progression. Unfortunately, collateral scores were
not collected in our study, and future studies are needed to confirm the above-mentioned
observations.
Our study did not assess perfusion status and included patients with a low ASPECTS regardless
of perfusion status because of the various perfusion vendors and thresholds used in different centers
depending on local institutional guidelines. Many of our centers use RAPID software, while others
use Viz.ai or Siemens software. Current guidelines support using ASPECTS only for patients in the
early window and the addition of perfusion images for patient selection in the extended window.1
There is an ongoing debate, however, regarding whether perfusion images are required to select
patients with large vessel occlusion in the extended window given that they may result in excluding
patients who otherwise may experience benefits associated with thrombectomy when perfusion
images are used.18,25,26 A secondary analysis of 591 patients in the HERMES data set showed a
constant benefit associated with thrombectomy among patients with a computed tomography
perfusion–estimated core infarct up to 150 mL.18 Furthermore, 4 of 5 ongoing clinical trials evaluating
MT for patients with a large core define a large core using the ASPECTS alone.
Finally, post-MT care represents another factor that modifies the outcomes of MT in general.
This care includes blood pressure control, decompressive hemicraniectomy protocols, and the use of
antiplatelets.27-29 Future studies are needed to evaluate the association of these factors with MT for
patients with a low ASPECTS.

Limitations
This study has some limitations, including the retrospective and observational design. In addition,
this was a multicenter study; therefore, management and procedural protocols were likely
heterogenous. Also, we did not have data regarding patients with a low ASPECTS treated with
medical management without MT in our database. Other limitations include that we did not have
data regarding diffusion images, the interrater agreement in scoring ASPECTS, or the breakdown of
ASPECTS points. Last, the ASPECTS was calculated by the investigators at the included sites and was
not adjudicated by a core laboratory.
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Conclusions
This cohort study suggests that more than 1 of 5 patients with an ASPECTS of 2 to 5 may achieve
90-day functional independence (mRS score of 0-2) with MT. Patients with an ASPECTS of 2 to 5 who
had successful recanalization were 5 times more likely to achieve a favorable 90-day outcome
compared with patients with unsuccessful recanalization. The association of a low ASPECTS with
90-day outcome did not differ between patients presenting in the early vs extended MT window.
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